Equities

Anixa Biosciences Inc

Anixa Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.45
  • Today's Change0.01 / 0.29%
  • Shares traded116.67k
  • 1 Year change+2.07%
  • Beta0.8640
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.36m
  • Incorporated1982
  • Employees4.00
  • Location
    Anixa Biosciences Inc3150 Almaden Expy Ste 250SAN JOSE 95118United StatesUSA
  • Phone+1 (408) 708-9808
  • Fax+1 (302) 655-5049
  • Websitehttps://www.anixa.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Metagenomi Inc55.93m-75.00m103.03m228.00--0.3824--1.84-2.53-2.531.687.190.1408--28.13236,987.30-18.88---22.14-------134.10------0.00--160.21---56.57------
Relmada Therapeutics Inc0.00-86.76m103.80m20.00--1.69-----2.88-2.880.002.040.00----0.00-89.88---100.40--------------0.00------37.09------
Regulus Therapeutics Inc0.00-35.39m104.75m31.00--1.07-----1.26-1.260.001.500.00----0.00-47.90-53.74-52.71-76.96-------715.58----0.00-------6.05--94.54--
Leap Therapeutics Inc0.00-60.34m107.14m54.00--1.63-----2.00-2.000.001.720.00----0.00-67.81-80.06-80.19-95.03-------7,900.37----0.00-------49.12------
Sagimet Biosciences Inc2.00m-29.25m108.82m10.00--0.5885--54.41-1.18-1.180.0785.740.019----200,000.00-27.79---29.32-------1,462.55------0.00------8.60------
Anixa Biosciences Inc0.00-12.36m110.70m4.00--5.08-----0.3906-0.39060.000.67720.00----0.00-50.54-59.69-52.50-62.61-------6,040.10----0.00-----28.3627.83------
Verastem Inc10.00m-89.49m111.88m73.00--3.96--11.19-3.34-3.340.37261.490.0672--2.00136,986.30-60.16-62.70-72.65-75.18-----894.91-406.17----0.5052---100.00---18.36------
Checkpoint Therapeutics Inc78.00k-42.47m113.45m23.00------1,454.42-1.50-1.500.0027-0.3720.0111--2.173,391.30-606.33-142.43---342.79-----54,444.87-6,554.97---------46.35-50.6117.21------
Annovis Bio Inc0.00-43.02m114.09m6.00---------4.42-4.420.00-0.14940.00----0.00-308.78-106.31-395.89-124.71-----------51.53---------121.90------
ALX Oncology Holdings Inc0.00-171.44m114.82m74.00--0.7177-----3.64-3.640.003.040.00----0.00-74.45-34.34-84.76-36.47-------7,238.76----0.0734-------30.23--14.30--
PDS Biotechnology Corp0.00-40.68m114.88m25.00--3.71-----1.23-1.230.000.84060.00----0.00-65.48-51.63-80.82-59.00-----------21.590.4409-------5.11------
Fibrobiologics Inc0.00-19.47m114.97m10.00---------0.939-0.9390.00-0.0730.00----0.00-171.13---333.35-----------------------272.15------
Assembly Biosciences Inc21.48m-45.61m115.43m65.00--3.33--5.37-9.32-9.324.285.470.2362--125.62330,476.90-50.15-39.69-69.22-44.03-----212.33-409.24----0.00-----13.5134.23---5.59--
Citius Oncology Inc0.001.93m116.23m--6.740.235260.11--0.2420.2420.006.930.00------3.25--3.35--------------0.036------535.30------
Cardiff Oncology Inc665.00k-40.88m118.24m31.00--2.21--177.80-0.9142-0.91420.01491.150.0081--2.1721,451.61-49.98-31.24-57.60-33.56-----6,143.91-7,819.23----0.00--26.425.22-7.07--157.91--
Data as of Sep 18 2024. Currency figures normalised to Anixa Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

14.80%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20241.38m4.32%
D.A. Davidson & Co. (Investment Management)as of 30 Jun 2024736.42k2.30%
LNW Wealth Management LLCas of 30 Jun 2024604.24k1.89%
UBS Financial Services, Inc.as of 30 Jun 2024530.54k1.66%
Mission Wealth Management LPas of 30 Jun 2024502.42k1.57%
Geode Capital Management LLCas of 30 Jun 2024330.58k1.03%
Bank of America, NA (Private Banking)as of 30 Jun 2024216.91k0.68%
Long Focus Capital Management LLCas of 30 Jun 2024165.70k0.52%
BlackRock Fund Advisorsas of 30 Jun 2024153.61k0.48%
Susquehanna Financial Group LLLPas of 30 Jun 2024112.39k0.35%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.